Cause analysis and control measures of common problems in clinical part from drug clinical trial data inspection

Gao-li HE,Tao ZENG,Wei ZHANG,Lin ZHANG,Xiao-yan ZHANG,Cong-jian XU
DOI: https://doi.org/10.14109/j.cnki.xyylc.2018.01.006
2018-01-01
Abstract:The clinical trial data inspection has achieved the phased objectives since China Food and Drug Administration issued the announcements about clinical trial data self-inspection and verification.This paper analyzed findings of clinical trial data inspections conducted from July 2015 to June 2017 and put forward corresponding control measures to common problems,which existed in the records and traceability of clinical data and medical examination,protocol compliance,investigational drug management,recording and reporting of safety information,screening and inclusion of subjects,obtaining of informed consent,and so on.
What problem does this paper attempt to address?